<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>refractory IBD &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/refractory-ibd/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 01:52:43 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>refractory IBD &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Dual-Targeted Therapy Brings Remission to Half of Patients with Hardest-to-Treat Inflammatory Bowel Disease</title>
		<link>https://bioengineer.org/dual-targeted-therapy-brings-remission-to-half-of-patients-with-hardest-to-treat-inflammatory-bowel-disease/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 01:52:43 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[advanced combination treatment]]></category>
		<category><![CDATA[anti-interleukin-23]]></category>
		<category><![CDATA[Crohn's disease]]></category>
		<category><![CDATA[dual targeted therapy]]></category>
		<category><![CDATA[guselkumab]]></category>
		<category><![CDATA[inflammatory bowel disease]]></category>
		<category><![CDATA[Janus kinase inhibitors]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[refractory IBD]]></category>
		<category><![CDATA[therapeutic drug monitoring]]></category>
		<category><![CDATA[ulcerative colitis]]></category>
		<category><![CDATA[upadacitinib]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=424415</guid>

					<description><![CDATA[A real-world study from Abu Dhabi found that pairing two advanced therapies with different mechanisms achieved combined clinical and biochemical remission in 52 percent of treatment courses among patients with inflammatory bowel disease refractory to a median of four prior advanced therapies.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">424415</post-id>	</item>
	</channel>
</rss>
